StockData
Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc. (FULC) stock

FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$3.71−0.06 (-1.59%)

Close on Nov 16, 2026Market cap $283.06MP/E –Yield –

Fulcrum Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Fulcrum Therapeutics's total assets was $323.95M at Jun 30, 2026. For fiscal 2025 it was $366.28M, up 40.5% from the year before. The highest annual figure on record is $366.28M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$366.28M+40.5%
FY2024Dec 31, 2024$260.72M+1.2%
FY2023Dec 31, 2023$257.69M+13.7%
FY2022Dec 31, 2022$226.69M-3.5%
FY2021Dec 31, 2021$235.00M+81.4%
FY2020Dec 31, 2020$129.58M+17.3%
FY2019Dec 31, 2019$110.44M+28.8%
FY2018Dec 31, 2018$85.77M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$323.95M+41.6%
Q1 FY2026Mar 31, 2026$346.77M+42.9%
Q4 FY2025Dec 31, 2025$366.28M+40.5%
Q3 FY2025Sep 30, 2025$214.86M-23.0%
Q2 FY2025Jun 30, 2025$228.84M-22.2%
Q1 FY2025Mar 31, 2025$242.65M+4.3%
Q4 FY2024Dec 31, 2024$260.72M+1.2%
Q3 FY2024Sep 30, 2024$279.01M+0.0%
Q2 FY2024Jun 30, 2024$294.26M-2.0%
Q1 FY2024Mar 31, 2024$232.59M-27.6%
Q4 FY2023Dec 31, 2023$257.69M+13.7%
Q3 FY2023Sep 30, 2023$278.88M+12.5%
Q2 FY2023Jun 30, 2023$300.33M+53.8%
Q1 FY2023Mar 31, 2023$321.12M+45.8%
Q4 FY2022Dec 31, 2022$226.69M-3.5%
Q3 FY2022Sep 30, 2022$247.81M-3.0%
Q2 FY2022Jun 30, 2022$195.23M+41.6%
Q1 FY2022Mar 31, 2022$220.25M+40.8%
Q4 FY2021Dec 31, 2021$235.00M+81.4%
Q3 FY2021Sep 30, 2021$255.55M+79.7%
Q2 FY2021Jun 30, 2021$137.88M-4.8%
Q1 FY2021Mar 31, 2021$156.48M+65.0%
Q4 FY2020Dec 31, 2020$129.58M+17.3%
Q3 FY2020Sep 30, 2020$142.22M+22.6%
Q2 FY2020Jun 30, 2020$144.86M+122.3%
Q1 FY2020Mar 31, 2020$94.86M+10.6%
Q4 FY2019Dec 31, 2019$110.44M–
Q3 FY2019Sep 30, 2019$115.96M–
Q2 FY2019Jun 30, 2019$65.15M–
Q4 FY2018Dec 31, 2018$85.77M–

More Fulcrum Therapeutics figures

See a number that looks wrong?